Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Trial Identifier: 3475-365
Sponsor: MSD
Start Date: November 2016
Primary Completion Date: October 2027
Study Completion Date: July 2028
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary - English

Trial Locations

Country Location
Denmark Glostrup, Denmark
Ireland Dublin, Ireland
Mexico Mexico City, Mexico
Netherlands Haarlem, Netherlands
Sweden Stockholm, Sweden
United Kingdom London, United Kingdom
United States, OR Portland, OR, United States, 97239
United States, TN Germantown, TN, United States, 38138
United States, WA Seattle, WA, United States, 98109